Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Affiliations

• ¹ Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. ykodera@med.nagoya-u.ac.jp.
• ² Department of Surgical Oncology, Gifu University, Gifu, Japan.
• ³ Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Ichikawa, Japan.
• ⁴ Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan.
• ⁵ Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
• ⁶ Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
• ⁷ Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
• ⁸ The University of Tokyo Graduate School of Mathematical Sciences, Tokyo, Japan.
• ⁹ Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.